Pylori Duo for Adjunctive Treatment and Prevention of Recurrence of Helicobacter Pylori Infection
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pylori Duo as an Adjunctive Treatment and for the Prevention of Recurrence of Helicobacter Pylori Infection
研究概览
地位
详细说明
This is a randomized, double-blind, placebo-controlled, single-center interventional clinical trial designed to evaluate the efficacy and safety of Pylori Duo as an adjunctive treatment in adult patients with confirmed Helicobacter pylori infection. Approximately 140 patients aged 18 to 70 years with a positive 13C-urea breath test and gastric biopsy performed before study initiation will be enrolled.
Participants will be randomly assigned to one of two parallel treatment groups. Group A will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with placebo for 10 days, followed by placebo for 3 months. Group B will receive the same standard quadruple therapy in combination with Pylori Duo for 10 days, followed by Pylori Duo for 3 months. Both investigators and participants will remain blinded to treatment allocation throughout the study.
The primary objective of the study is to evaluate the effect of Pylori Duo on the management of gastrointestinal adverse effects associated with standard eradication therapy. Secondary objectives include evaluation of H. pylori eradication rate, recurrence of infection at 3 and 12 months after treatment, gastrointestinal symptoms assessed using the Gastrointestinal Symptom Rating Scale (GSRS), gastrointestinal quality of life assessed using the Nepean Dyspepsia Index-Short Form (NDI-SF), and safety and tolerability. Safety assessments will include the recording of adverse events, evaluation of their potential relationship to the study product, and treatment adherence monitoring.
Participants will attend scheduled follow-up visits during treatment and post-treatment follow-up. A 13C-urea breath test will be performed 6 to 8 weeks after completion of Phase I treatment to assess eradication. Follow-up will continue for 3 months after treatment completion, and a telephone assessment will be conducted at 12 months to evaluate recurrence. Statistical analyses will be performed using both intention-to-treat and per-protocol populations.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Juan Antonio Carrillo, Medicine
- 电话号码：+34 647725527
- 邮箱：carrillo@unex.es
学习地点
-
-
Badajoz
-
Don Benito、Badajoz、西班牙、06400
- GALA Laboratories
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Adults aged 18 to 70 years.
- Confirmed Helicobacter pylori infection prior to treatment, as determined by a positive 13C-urea breath test (13C-UBT) and gastric biopsy.
- No previous H. pylori eradication therapy.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Significant underlying conditions that, in the opinion of the treating physician, would preclude participation in the study, including hepatic insufficiency (aspartate aminotransferase or alanine aminotransferase >3 times the upper limit of normal), renal insufficiency (creatinine ≥2.0 mg/dL or glomerular filtration rate <50 mL/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%, thyroid disease, pulmonary disease, or any other serious medical condition.
- Pregnancy, breastfeeding, or unwillingness to use contraception during the study.
- Active gastrointestinal bleeding.
- History of upper gastrointestinal tract surgery.
- History of allergic reactions to medications included in the treatment regimen.
- Use of bismuth-containing agents, antibiotics, proton pump inhibitors, or other relevant medications within 4 weeks prior to treatment.
- Behaviors that may increase the risk of illness, including excessive alcohol consumption or substance abuse.
- Negative repeat urea breath test prior to treatment initiation.
- Unwillingness or inability to provide informed consent.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较：Standard Quadruple Therapy + Placebo
Participants assigned to this arm will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with placebo for 10 days during Phase I, followed by placebo for 3 months during Phase II.
|
Omeprazole will be administered as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylera® will be administered in combination with omeprazole as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Placebo capsules identical in appearance to Pylori Duo, but without pharmacologically active ingredients, will be administered in combination with standard quadruple therapy for 10 days, followed by placebo for 3 months during the post-treatment phase.
|
|
实验性的：Standard Quadruple Therapy + Pylori Duo
Participants assigned to this arm will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with Pylori Duo for 10 days during Phase I, followed by Pylori Duo for 3 months during Phase II.
|
Omeprazole will be administered as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylera® will be administered in combination with omeprazole as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylori Duo is a dietary supplement containing Lactobacillus rhamnosus and dried licorice extract.
Participants assigned to the experimental arm will receive Pylori Duo in combination with standard quadruple therapy for 10 days, followed by Pylori Duo for 3 months during the post-treatment phase.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Gastrointestinal adverse effects associated with standard eradication therapy
大体时间：Up to 3 months after treatment initiation
|
Assessment of the effect of Pylori Duo on the management of gastrointestinal adverse effects associated with standard Helicobacter pylori eradication therapy.
Gastrointestinal tolerability will be evaluated during the treatment period and follow-up.
|
Up to 3 months after treatment initiation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Helicobacter pylori eradication rate
大体时间：6 to 8 weeks after completion of the 10-day treatment phase
|
Eradication of H. pylori will be assessed by negative 13C-urea breath test performed 6 to 8 weeks after completion of Phase I treatment.
Gastric biopsy may also be considered according to protocol-defined diagnostic assessment.
|
6 to 8 weeks after completion of the 10-day treatment phase
|
|
Recurrence of Helicobacter pylori infection
大体时间：3 months and 12 months after completion of treatment
|
Recurrence of H. pylori infection will be evaluated during follow-up at 3 and 12 months after treatment based on post-treatment clinical assessment and protocol-defined follow-up procedures.
|
3 months and 12 months after completion of treatment
|
|
Change from baseline in Gastrointestinal Symptom Rating Scale overall score
大体时间：Baseline and 3 months after treatment initiation
|
Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale.
Each item is scored from 1, indicating no troublesome symptoms, to 7, indicating very troublesome symptoms.
The overall score is calculated as the mean of the 15 item scores and ranges from 1 to 7. Higher scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.
Change from baseline will be evaluated during the follow-up period.
|
Baseline and 3 months after treatment initiation
|
|
Change from baseline in Short Form Nepean Dyspepsia Index total score
大体时间：Baseline and 3 months after treatment initiation
|
Gastrointestinal health-related quality of life will be assessed using the 10-item Short Form Nepean Dyspepsia Index.
The total score ranges from 0 to 100.
Higher scores indicate better gastrointestinal health-related quality of life and therefore a better outcome.
Change from baseline will be evaluated during the follow-up period.
|
Baseline and 3 months after treatment initiation
|
|
Participants with adverse events
大体时间：Up to 3 months after the first dose
|
Number and percentage of participants who experience at least one adverse event during the assessment period.
|
Up to 3 months after the first dose
|
|
Participants with study product-related adverse events
大体时间：Up to 3 months after the first dose
|
Number and percentage of participants who experience at least one adverse event considered by the investigator to be related to the study product.
|
Up to 3 months after the first dose
|
|
Treatment adherence
大体时间：Up to 3 months after the first dose
|
Treatment adherence will be reported as the percentage of prescribed study product doses taken.
The percentage will be calculated as the number of doses taken divided by the number of doses prescribed, multiplied by 100.
Higher percentages indicate greater treatment adherence.
|
Up to 3 months after the first dose
|
合作者和调查者
调查人员
- 首席研究员：Sergio Chamorro Benítez, Medicine、Hospital Parque Vegas Altas, Don Benito (Badajoz)
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 20260836
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.